PGE2 mediates autocrine and paracrine signaling by binding to G-protein coupled receptors (EP1, EP2, EP3, EP4) on the cell surface, functioning to modulate phospholipase C and adenylate cyclase activity. PGE2 ha
PGE2 mediates autocrine and paracrine signaling by binding to G-protein coupled receptors (EP1, EP2, EP3, EP4) on the cell surface, functioning to modulate phospholipase C and adenylate cyclase activity. PGE2 has been of great interest as a therapeutic target, either by modulation of its synthes...
PGE2 mediates autocrine and paracrine signaling by binding to G-protein coupled receptors (EP1, EP2, EP3, EP4) on the cell surface, functioning to modulate phospholipase C and adenylate cyclase activity. PGE2 has been of great interest as a therapeutic target, either by modulation of its ...
Doxorubicin receptors, EP2/EP4 receptors, on the treatment surface of leads to MDSCs PtoGaEc2tirvealeteasPeKfrAomancdaAncMerPcKelslisg. nPaGliEn2gc, ainndtuarcgeet production of miR-10a and enhance AMPK signaling in MDSCs. This signaling cascade turns on expansion and polarization of MDSCs ...
(GPCRs), including EP1, EP2, EP3 and EP4, and further causing various downstream effects [13]. PGE2is considered a promising candidate molecule to improve tissue repair and regeneration in ischemic disease [13,15]. The available evidence suggests that PGE2could ameliorate tissue ischemia by ...
MSCs enhanced p-AMPKα(phosphorylated AMPK) levels in M1 cells and reduction in p-mTOR (phosphorylated mTOR) was observed in macrophages from both M1- as well as M2-MSC co-cultures, further solidifying the MSC-induced metabolic shifts in macrophages from high energy demanding to a low ...
(EP1, EP2, EP3, EP4) on the cell surface, functioning to modulate phospholipase C and adenylate cyclase activity. PGE2 has been of great interest as a therapeutic target, either by modulation of its synthesis by COX inhibitors (NSAIDS) or by modulation of its receptors by downregulation or ...